Evidence map›Paper›PMID 39594487›Full record

ArticleAntioxidants (Basel, Switzerland)2024

First Report on Cationic Triphenylphosphonium Compounds as Mitochondriotropic H

Tobias Werner, Tito Añazco, Paula Osses-Mendoza, Alejandro Castro-Álvarez, Cristian O Salas, Raquel Bridi, Holger Stark, Christian Espinosa-Bustos

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tobias WernerInstitute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, 40225 Duesseldorf, Germany.ORCID 0000-0002-7243-5826
Tito AñazcoDepartamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.
Paula Osses-MendozaDepartamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.ORCID 0009-0004-4752-2700
Alejandro Castro-ÁlvarezDepartamento de Ciencias Preclínicas, Facultad de Medicina, Universidad de La Frontera, Temuco 4780000, Chile.ORCID 0000-0001-8360-8027
Cristian O SalasDepartamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.ORCID 0000-0001-7620-2459
Raquel BridiDepartamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380000, Chile.ORCID 0000-0002-3891-5770
Holger StarkInstitute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, 40225 Duesseldorf, Germany.ORCID 0000-0003-3336-1710
Christian Espinosa-BustosDepartamento de Farmacia, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.ORCID 0000-0001-6038-8439

Funding

VRI-PUC PUENTE
6 · The paper itself

Abstract

Neurodegenerative diseases are a major public health problem due to the aging population and multifaceted pathology; therefore, the search for new therapeutic alternatives is of the utmost importance. In this sense, a series of six 1-(3-phenoxypropyl)piperidines alkyl-linked to a triphenylphosphonium cation derivative were synthesized as H

Indexed as

antioxidantshistamine 3 receptormolecular dockingmolecular dynamicsneurodegenerative diseasestriphenylphosphonium cation

Identifiers

PMID39594487
PMCPMC11591188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.